Brought to you by:
Stryker completes acquisition of Inari Medical
Stryker announced today that it has completed the acquisition of Inari Medical. A press release notes that the addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing venous thromboembolism (VTE) segment. “The acquisition of Inari…
FlowTriever device found to dramatically improve breathing among intermediate-risk acute pulmonary embolism patients
SCVS 2024 saw Zachary AbuRahma, DO, an assistant professor of vascular surgery at West Virginia University and the Charleston Area Medical Center in Charleston, West Virginia, presented data from a single-center experience focused on the use of the FlowTriever device…
FLAME, FLASH and ongoing PEERLESS trials collect ‘compelling’ data for FlowTriever device
Speaking on the FLAME, FLASH and PEERLESS trials that each collected data on the FlowTriever (Inari Medical) device for the treatment of pulmonary embolism (PE), Ripal Gandhi, MD, Miami Cardiac & Vascular Institute & Miami Cancer Institute, Miami, elaborated on…
FLASH results demonstrate ‘excellent safety profile’ of the FlowTriever system in full US cohort
Results of the FLASH registry demonstrate the “excellent safety profile” of the FlowTriever system (Inari Medical) in 800 real-world patients. This is according to Catalin Toma, MD, from the University of Pittsburgh Medical Center, Pittsburgh, who presented outcomes for the…
Clinical outcomes of the ClotTriever system in DVT set to be evaluated in RCT
Inari Medical has announced planned enrollment of the DEFIANCE randomized controlled trial (RCT), which is designed to compare the clinical outcomes of patients with iliofemoral deep vein thrombosis (DVT) treated with the ClotTriever system versus anticoagulation only. The trial will enroll 300 patients…
First patient enrolled in PEERLESS study of FlowTriever system
Inari Medical has announced that the first patient has been enrolled in PEERLESS prospective, randomized controlled trial (RCT) comparing the outcomes of patients with intermediate-high risk pulmonary embolism (PE) treated with the FlowTriever system versus catheter-directed thrombolysis (CDT). The first…